Latest News
-
April 14th, 2009
Novosom publishes Data on novel anti-inflammatory therapeutic approach targeting CD40 >> -
August 26th, 2008
Novosom AG acquires exclusive license from Isis Pharmaceuticals, Inc. for CD40-targeted antisense inhibitors >>
SMARTICLES®
for nucleic acid delivery
See how our technology works >>
Welcome
novosom AG is a biopharmaceutical company with a pioneering, fully charge-reversible liposomal technology for the delivery of DNA based therapeutics. novosom's SMARTICLES® allow the delivery of siRNA, antisense or decoy oligonucleotides inside the cell for either topical or systemic applications.
In collaboration with its partners, novosom is developing unique therapeutics based on oligonucleotides in inflammation, oncology and liver diseases. In addition, the Company is developing its own pipeline in autoimmune diseases and is licensing SMARTICLES® for target validation approaches.
novosom is located in Halle, Germany.